论文部分内容阅读
原发性肺动脉高压(PPH)的治疗方法包括血管扩张剂、抗凝剂和心肺移植。有几种血管扩张剂可使重症患者的血液动力学和症状得以改善,但有些研究表明,此类药物有严重的副作用且疗效欠佳。前列环素(PGI_2)为强力血管扩张剂和血小板在血管内皮聚集的抑制剂,用于PPH 和ARDS 患者可降低肺血管阻力、增加心输出量和氧释放.本文为前瞻性随机和不随机观察PGI_2对PPH 患者血液动力学和运动耐力的长期疗效.
Treatment of primary pulmonary hypertension (PPH) includes vasodilators, anticoagulants and cardiopulmonary transplantation. Several vasodilators can improve hemodynamics and symptoms in critically ill patients, but some studies show that these drugs have serious side effects and poor efficacy. Prostacyclin (PGI_2), a potent vasodilator and an inhibitor of platelet aggregation in the vascular endothelium, can reduce pulmonary vascular resistance and increase cardiac output and oxygen release in patients with PPH and ARDS.This prospective randomized and nonrandomized observation Long-term effects of PGI_2 on hemodynamics and exercise tolerance in patients with PPH.